{"prompt": "['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 33 of 74', '10.5 Follow-up if stopping treatment at or beyond disease', 'progression', 'Patients will be followed-up every three months (+7 days) after disease progression', 'for a minimum of 9 months from randomisation. At every three month follow-up, the', 'following assessments should be completed:', 'Concomitant medication assessment', 'ECOG and Karnofsky performance status', 'Physical Examination, Weight & Blood Pressure', 'QoL questionnaires', '10.6 End of Trial Participation', \"A patient's participation in the trial will finish at the end of trial declaration (a minimum\", 'of 9 months from randomisation of the last patient). Following the end of the trial', 'patients may remain on dabrafenib and trametinib if the treating physician believes it is', \"in the patients' best interest to do so. Once the trial has closed, the choice of schedule\", 'and doses will be at the discretion of the treating physician.', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 34 of 74', '10.7 Schedule of Assessments', 'Cycle 1', 'Cycle 2', 'Cycle 3', '4-weekly', '3-Monthly', 'Screening', 'onwards\u00b9', 'End of', 'Follow-up', 'Disease', 'Follow-up', 'Pre-', 'randomisation', 'Day 1', 'Day', 'Day', 'Day', 'Day 1', 'Treatment', '(prior to', 'Progression', 'after', '15', '1', '15', 'progression\u00b9', 'progression', '-28 days', '+2 days', '+ 30 days', '+7 days', '+7 days', '+7 days', 'Inclusion/Exclusion Assessment', 'X', 'Informed Consent', 'X', 'Medical History\u00b2', 'X', 'Pregnancy Test', 'X', 'Physical Examination, weight &', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Blood pressure', 'Baseline Skin Record', 'X', 'ECG\u00b3', 'X', 'ECHO', 'X4', 'X5', 'Concomitant medication', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'assessment', 'Compliance Assessment', 'X', 'X', 'X', 'AE assessment', 'X', 'X', 'X', 'X', 'X', 'Skin Toxicity Questionnaire6', 'X', 'X', 'X', '(Patient and Clinician)', 'ECOG and Karnofsky Performance', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Status', 'Haematology7 & Biochemistry8', 'X', 'X', 'X', 'RECISTv1.1 Disease measurement9', 'X10', 'X11', 'Every 8 weeks (7 days) until protocol defined disease', 'X', 'progression11', 'Prescription & Dispensing12', 'X', 'Treatment w/ dab+tram - Std arm', 'dab + tram D1-28', 'Treatment w/ dab+tram - Exp arm', 'dab D1-21 + tram D1-14', 'QoL Questionnaires', 'X', 'Every 12 weeks13', 'X', 'X', 'Research blood sample', 'X', 'X', 'X', 'X', 'Cycle 4, day 1', 'and then', 'every other', 'cycle', 'PK sampling14', 'X', 'X', 'X', 'Cycle 4, day 1', 'and then', 'every other', 'cycle', 'Tumour tissue15', 'X', 'Patient Experience Survey', 'X16', '9 months after randomisation17', 'Patient Experience Interview', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 35 of 74', '1)', 'If patients have been on treatment, or progression-free follow-up, for more than 52 weeks, clinic visits can', 'be', 'every', 'other', 'cycle, with telephone follow-up to ensure patient review is at least every cycle until progression', '2)', 'To include confirmation of disease diagnosis, stage and BRAF mutation status', '3)', 'Then as clinically indicated', '4)', 'Screening ECHO to be done prior to randomisation in patients with a cardiac history including current hypertension defined', 'as systolic BP > 140mm Hg or diastolic BP > 90mm Hg, or requirement for regular cardiac medication (other', 'than', 'aspirin', 'or statin), or an abnormal ECG. In patients without a cardiac history who are normotensive with a normal ECG, the', 'baseline ECHO should be done prior to Cycle 1 day 15 and is not mandated prior to randomisation.', '5) ECHOs are recommended to be repeated during cycle 5 and every 12 weeks thereafter whilst on treatment (ie. during', 'cycles 8, 11, 14 etc.) as per SmPC guidance. The LVEF should be within normal limits to commence/continue treatment.', '6)', 'If Skin AEs are reported, skin specific questionnaires to be completed', '7) Haematology: WBC, differential ANC, Platelets, Hb (Not required Cycle 1, day 1 if within 2 weeks of screening)', '8)', 'Biochemistry: Urea, Na, K, GGT, ALT or AST,total bilirubin, albumin, total protein, Serum creatinine, Creatinine Clearance,', 'serum calcium, ALP, LDH (Not required Cycle 1, day 1 if within 2 weeks of screening)', '9)', 'Disease measurement will use CT/MRI scans (and ruler) and RECIST version 1.1', '10)', 'Baseline', 'imaging to include head aswell as chest/abdo/pelvis. If head scan is clear, imaging of head to follow local practice', 'but recommended to be repeated at least every 16 calendar weeks', '11) Imaging to be performed at or during week 6, then every 8 calendar weeks until disease progression. If follow-up', 'continues prior to disease progression beyond 52 calendar weeks since start of treatment than imaging can be reduced to', 'every 12 calendar weeks.', '12) Prescription & dispensing should be within 2 days prior to the first dose of each cycle, which should start', 'with', 'the', 'morning', 'dose', '13) Quality of Life Questionnaires to be completed every 12 calendar weeks at the closest clinical visit', '14) In a subset of consenting patients only, PK samples to be collected, see section 13 for further details', '15) Archival tumour block to be requested prior to randomisation; tumour sample to be collected from any resected/biopsied', 'progression lesion', '16)', 'Consent Process Patient Experience Survey', '17) Treatment Patient Experience Survey', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']\n\n###\n\n", "completion": "END"}